A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (NCT05981703)

🧪 Interventions in This Study

• BGB-26808 (DRUG)
• Tislelizumab (DRUG)
• Chemotherapy (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

• City of Hope National Medical Center — Duarte, California
• University of Southern California Norris Comprehensive — Los Angeles, California
• Yale University Yale Cancer Center — New Haven, Connecticut
• Sylvester Cancer Center, University of Miami — Miami, Florida
• University of Michigan Health System — Ann Arbor, Michigan
• John Theurer Cancer Center Hackensack University Medical Center — Hackensack, New Jersey
• Icahn School of Medicine At Mount Sinai — New York, New York
• Providence Portland Medical Center — Portland, Oregon
• The University of Texas Md Anderson Cancer Center — Houston, Texas
• Southside Cancer Care — Miranda, New South Wales
• Macquarie University — North Ryde, New South Wales
• Icon Cancer Centre Kurralta Park — Kurralta Park, South Australia
• Linear Clinical Research — Nedlands, Western Australia
• The First Affiliated Hospital of Anhui Medical Universitygaoxin Branch — Hefei, Anhui
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
• Hubei Cancer Hospital — Wuhan, Hubei
• Tongji Hospital,Tongji Medical College of Hustsino French New City Branch — Wuhan, Hubei
• The First Hospital of China Medical University Hunnan Branch — Shenyang, Liaoning
• Jining No1 Peoples Hospital West Branch — Jining, Shandong
• Yantai Yuhuangding Hospital — Yantai, Shandong
• Shanghai East Hospital Branch Hospital — Shanghai, Shanghai Municipality
• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality
• Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital — Chengdu, Sichuan
• Hangzhou First Peoples Hospital — Hangzhou, Zhejiang
• Taizhou Hospital of Zhejiang Province (East) — Taizhou, Zhejiang

📞 Contact the Study Coordinator

Phone: (877) 828-5568

Email: clinicaltrials@beonemed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.